IDEA Collider: Innovation & Asymmetric Learning in Pharma

In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO 2026 and some of the key clinical datasets that could shape the next phase of oncology innovation.

Together, they discuss whether T-cell engagers can deliver transformative survival benefits in earlier lines of solid tumours with tarlatamab in DeLLphi-305; the promising science behind PD-1×VEGF combinations with Ivonescimab in HARMONi-GI1 and how we believe Merck & Co., Inc. are perceiving them; and Krascendo 1, a true head-to-head study that could help define a best-in-class KRAS G12C therapy and shape the future of the treatment landscape.

Listen now to hear which studies the team are most excited about - and share the ESMO data you will be watching most closely. The IDEA and SAI teams will be in Madrid and look forward to connecting with colleagues to discuss the implications further.

www.ideapharma.com

www.sai-med.com

Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at SAI. Together, they explore how artificial intelligence and synthetic behavioral modeling are transforming pharmaceutical market research and insight generation.

For decades, market research operated under a strict constraint: you could choose two between speed, price, and quality, but never all three.

Rebecca and Kwame discuss how synthetic user technology breaks this triangle, allowing biopharma teams to generate high-quality qualitative insights rapidly and cost-effectively. Kwame breaks down the architecture behind synthetic users—defining them as an abstraction of brain architecture that replicates human emotional responses, cognitive biases, and system 1 behaviors rather than striving for super intelligence. Rebecca shares real-world case studies in rare diseases, competitive simulation workshops, and creative concept testing where synthetic personas achieved over 90% parity with live human respondents.

Tune in to discover how synthetic research is empowering healthcare leaders to make faster, higher-confidence decisions across the thousands of choices required to bring a medicine to market.

Keep up with the Guests

• Rebecca Gould's LinkedIn: https://www.linkedin.com/in/rebecca-gould-b30b73/
• Kwame Ferreira's LinkedIn: https://www.linkedin.com/in/kwame-ferreira-1b06a31/

Keep up with Rick Ritacco:

• LinkedIn: https://www.linkedin.com/in/rritacco/

Follow IDEA Pharma On;

• Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer immunotherapy. As the industry prepares for the upcoming patent expiration of Merck's dominant checkpoint inhibitor Keytruda, companies are racing to claim the next oncology backbone.

We analyze the three major strategies currently shaping the pipeline: Merck’s platform defense focusing on subcutaneous formulations and early-stage curative intent; the high-risk, high-reward displacement play of PD-1/VEGF bispecific inhibitors spearheaded by players like Akeso and Summit; and AstraZeneca’s tailored, tumor-specific approach combining immunotherapy with antibody-drug conjugates (ADCs) and targeted small molecules. The guests also dissect key clinical insights from the HARMONY-6 Phase 3 trials, the biological and tumor-localization benefits of dual-mechanism molecules over dual-drug cocktails, and the strategic importance of choosing between incremental portfolio expansion and blockbuster-seeking big bets.

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Alex Gray; LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/

Keep up with David Radwaner; LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/

Keep up with Tom Brockbank; LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/

Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30 years, MS therapies have primarily focused on controlling inflammation and visible relapses. Jason argues it’s time to look deeper and address the ongoing neurodegeneration driving long-term disability, known as Progression Independent of Relapse Activity (PIRA).

We explore Immunic's investigational therapy, vidofludimus calcium, and its unique dual-mechanism approach: acting as a DHODH inhibitor for anti-inflammatory benefits while also activating the Nurr1 nuclear receptor to potentially provide direct neuroprotection. Jason shares insights from the EMPHASIS and CALIBER clinical trials, discusses why the industry needs safer immunomodulators rather than just broad immunosuppressants (especially as the MS population ages), and shares a fascinating biological link between MS remission during pregnancy and Nurr1 levels. Tune in to hear what the next 10 to 15 years hold for MS patients, including the ultimate goals of halting progression entirely and achieving remyelination.

Episode Timestamps

00:00:00 - Introduction: Meet Jason Tardio, President and COO of Immunic.

00:02:01 - The Evolution of MS Treatment: Transitioning from purely anti-inflammatory approaches to addressing underlying neurodegeneration.

00:04:29 - What is PIRA?: Understanding Progression Independent of Relapse Activity and why patients still accumulate disability.

00:10:30 - The Dual-Mechanism Approach: How vidofludimus calcium combines DHODH inhibition with Nurr1 activation.

00:13:33 - The Power of Nurr1: Exploring the target's role in neuronal survival and the fascinating biological link to pregnancy in MS patients.

00:18:14 - Clinical Validation: Analyzing data from the EMPHASIS (relapsing MS) and CALIBER (progressive MS) trials.

00:27:42 - Standing Out in a Crowded Market: Why safety, tolerability, and avoiding broad immunosuppression matter, especially for aging MS patients facing immunosenescence.

00:36:08 - The Next 10 Years: Moving towards halting progression, potential remyelination, and the need to reclassify MS beyond relapsing and progressive labels.

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Jason Tardio;

LinkedIn: https://www.linkedin.com/in/jason-tardio/

Keep up with Rick Ritacco:

LinkedIn: https://www.linkedin.com/in/rritacco/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine. With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new FDA prioritizations and breakthrough clinical data.

Athina shares insights from her meta-analysis on psilocybin and discusses the unique methodological challenges facing the industry, such as blinding integrity and the influence of expectancy effects in clinical trials. We explore the debate over whether the "psychedelic experience" is necessary for therapeutic benefit and how biotechs are balancing regulatory-friendly trial designs with patient safety.

Finally, Athina looks toward the future of precision psychiatry, examining the role of biomarkers and the immense logistical challenges of scaling these intensive therapies within global healthcare systems.

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Athina Metaxa; LinkedIn:

https://www.linkedin.com/in/athina-marina-metaxa/

Follow IDEA Pharma On; Website:

https://www.ideapharma.com/

Listen to more fantastic podcast episodes:

https://ideacollider.simplecast.com/

Welcome to IDEA Collider with your host, Rick Ritacco.

In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts into relevant narratives. Sue discusses the unique challenges biotechs face with early positioning, explaining why teams often struggle with the paradox of having immediate scientific certainty about a molecule but immense clinical uncertainty about its future.

We explore how to simplify scientific messaging without "dumbing it down," and Sue shares three proven strategies: reappropriating non-pharma nomenclature, evolving familiar drug classes, and focusing on tangible clinical outcomes. Sue also highlights the importance of cross-functional alignment, noting that a team's conviction to execute a narrative often matters more than having absolute precision.

Tune in to hear her hilarious origin story involving the Boston Globe and oat bran donuts, and learn actionable advice on what biotechs should immediately remove from their websites.

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Sue Wood; LinkedIn: https://www.linkedin.com/in/susan-wood-266631244/

Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.

This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA

They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one.

The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.

They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.

Episode Timestamps:

00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.

00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.

00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.

00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.

00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.

00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.

00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.

00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Alex Gray;

LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/

Keep up with David Radwaner;

LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/

Keep up with Tom Brockbank;

LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/

Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.

While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach.

Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development.

The conversation also highlights Anocca’s first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms.

This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine.

Episode Timestamps

00:00 – Introduction to TCR-T and solid tumor challenges

00:48 – Meet Reagan Jarvis and Anocca

02:05 – From New Zealand to Sweden: founder journey

03:08 – Frustration that sparked the platform

04:33 – Why CAR-T struggles in solid tumors

07:24 – The advantage of vertical integration in biotech

09:23 – First non-viral clinical trial challenges

10:56 – Umbrella trials in pancreatic cancer (KRAS focus)

14:13 – Biomarkers and building a target library

17:08 – Software, data, and machine learning in TCR discovery

18:08 – Regulatory pathways for individualized therapies

19:19 – Commercial landscape and target bottlenecks

22:29 – Expanding beyond oncology and partnerships

23:51 – Building a biotech company in Sweden

27:12 – Misconceptions about T-cell biology

30:04 – Milestones and 5-year vision

32:32 – Advice for scientific founders

34:17 – Closing thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Reagan Jarvis;

LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/

Website: https://www.anocca.com/

Follow IDEA Pharma

Website: https://www.ideapharma.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations.

After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation.

The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment.

They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology.

Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth.

This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode

Timestamps

00:00 – Introduction and Vir’s transformation story

00:40 – Marianne De Backer’s 30+ year pharma journey

02:42 – Vir’s origins and post-COVID strategic pivot

04:42 – Taking over as CEO during a crisis

06:33 – Lessons from the biotech downturn (“biotech winter”)

08:56 – Astellas partnership and T-cell engager strategy

09:52 – ProXtend platform: masked T-cell engagers explained

13:24 – Clinical data, safety, and tumor targeting

15:32 – Integrating new teams and scientific expertise

17:38 – Expanding the pipeline (HER2, EGFR, oncology)

19:50 – Hepatitis delta program and commercialization plans

22:11 – Funding strategy and biotech market outlook

25:37 – FDA interactions and regulatory perspective

28:13 – AI in drug discovery and clinical trials (Daisy platform)

31:34 – Culture: grit, ingenuity, collaboration, authenticity

34:21 – Personal reflections and leadership mindset

35:46 – Closing thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Marianne De Backer;

LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/

Website: https://www.vir.bio/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation.

Episode Timestamps;

00:00 Welcome to Idea Collider

00:18 Kymera 2026 Catalysts

02:33 De Risking with Degraders

02:54 Targeted Protein Degradation 101

06:20 KT-621 STAT6 Degrader

08:16 Rethinking Type 2 Disease Treatment

12:21 Nello’s Path to CEO

16:32 Building a Standalone Biotech

23:19 Partnering with Big Pharma

26:51 Culture and Office Energy

32:03 Capital Plan and Potential Launches

36:24 Belief and Execution Mindset

39:00 Life Outside the Lab

40:07 Where to Follow Kymera

40:35 Closing Thanks

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Nello Mainolfi & Kymera

LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/

Website: https://www.kymeratx.com/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making.

Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston, and Lucia Fernandez Barreiros, this conversation examines how cross-functional teams can interpret insights, manage uncertainty, and improve portfolio outcomes in complex drug development environments. The discussion covers artificial intelligence, asymmetric learning, forecasting challenges, strategic alignment, and the leadership mindset required to navigate innovation in biopharma.

SAI MedPartners is a global consultancy that provides strategic insights, competitive intelligence, market research, and commercialization strategy to pharmaceutical, biotechnology, and medical device companies across the product lifecycle. This episode is a must-listen for leaders working across drug development, commercialization strategy, and pharmaceutical innovation.

Keep up with the guests;

Erik Nordhoy - President at SAI MedPartners LLC https://www.linkedin.com/in/erik-nordhoy-6996241/

John Barry - Executive Vice President at SAI MedPartners LLC https://www.linkedin.com/in/johnnbarry/

Matt Boucher, PhD - Director, Oncology BU, SAI MedPartners LLC https://www.linkedin.com/in/matthewbchr/

Jennifer Preston - VP, Artificial Intelligence Leader, SAI MedPartners LLC https://www.linkedin.com/in/jennifer-j-preston/

Lucia Fernandez Barreiros - Consulting Analyst, SAI MedPartners LLC https://www.linkedin.com/in/lucia-fernandez-barreiros-ba5260224/

Follow Mike Rea On;

Website: https://ideacollider.simplecast.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases.

Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform.

Episode Timestamps;

00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma

00:19 Meet Michelle Werner: Leading Alltrna’s tRNA Platform

02:09 From Cancer Clinic to Pharma: A Patient-First Career Path

06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style

09:37 Vulnerability & Psychological Safety: Building High-Trust Teams

11:46 A Personal Turning Point: Her Son’s Duchenne Diagnosis

17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation

18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna

22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions

28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines

33:49 From Preclinical to First-in-Human: Alltrna’s 2026 Milestones

36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease’s Inflection Point?

Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options.

This episode highlights a pivotal question for the industry:

Are rare diseases at the same inflection point oncology experienced two decades ago?

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Michelle Werner;

LinkedIn: https://www.linkedin.com/in/michelle-c-werner/

Website: https://www.alltrna.com/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project.

Episode Timestamps;

00:00 Introduction and Welcome

00:27 Rick's Background and Project Overview

02:31 Client Team Introductions

05:32 Collaboration and Challenges

13:29 Defining the Mechanism and Market Positioning

23:52 Communication and Alignment

27:48 Navigating Internal and External Communication

33:15 Launch, Reflections, and Lessons Learned

41:14 Final Thoughts and Acknowledgements

Keep up with the guests;

• Robyn Blackburn - Director Global Commercial Strategy CAR-T at Kite Pharma

• https://www.linkedin.com/in/robyn-blackburn-805b8b13/

• Jayne Butler - Director of Strategic Initiatives at Fingerpaint Branding

• https://www.linkedin.com/in/jaynebutler/

• Tracey Sacco - Former SVP Global Strategic Marketing at Acceleron

• https://www.linkedin.com/in/tracey-sacco-53 2a034/

• Rick Ritacco - Head of Growth and Innovation

• https://www.linkedin.com/in/rritacco/

Follow Mike Rea On;

Website: https://ideacollider.simplecast.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease.

Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech founder, and now leader inside a global pharmaceutical company. The conversation explores how human genetics, CRISPR base editing, lipid nanoparticle delivery, and asymmetric learning converged to create a potential lifelong solution to cardiovascular disease.

They also dive deep into the ethics of gene editing, global access and pricing, early intervention versus chronic care, FDA regulatory challenges, and what the Verve–Lilly acquisition means for the future of cardiometabolic medicine.

This episode is a must-listen for anyone interested in biotech innovation, gene therapy, cardiovascular disease, and the future of preventive medicine.

00:00 Introduction and Guest Welcome

01:16 Sekar Kathiresan's Early Life and Education

03:19 Founding Verve and Transition to Entrepreneurship

05:35 The Science Behind Verve's Mission

10:27 Challenges and Breakthroughs in Gene Editing

20:05 Regulatory Hurdles and First Human Trials

25:11 Ethical Considerations in Gene Editing

27:06 Introduction to Drug Delivery and Ethical Considerations

27:51 Historical Context and Pioneers in Medical Procedures

28:35 Commercial and Ethical Challenges in Medicine

29:32 Innovations in Cardiovascular Treatments

32:49 The Role of Gene Editing in Long-term Health

37:55 Strategic Partnerships and Industry Insights

45:08 Reflections on the US Medical Ecosystem

48:54 Conclusion and Future Outlook

Keep up with Sekar Kathiresan;

LinkedIn: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/

Website: https://www.lilly.com/

Follow Mike Rea On;

Website: https://ideacollider.simplecast.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.

The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation!

00:00 Welcome to Idea Collider

00:04 Introducing Alex Telford

01:59 Alex's Journey from UCL to Convoke Bio

05:29 The Mission and Work of Convoke Bio

07:57 Challenges in Pharma Decision Making

14:05 The Role of AI in Pharma

18:26 Knowledge Management and AI

27:58 Staying Updated in the Fast-Moving AI Field

30:25 AI's Impact on Industry Economics

31:38 AI in Clinical Trials and Drug Development

35:56 China's Role in Drug Discovery

39:24 Neuroscience and AI: Blurring the Lines

46:05 Future Predictions in Pharma

51:20 Addressing Cognitive Bias in Pharma

53:13 Concluding Thoughts and Future Directions

Keep up with Alex Telford;

LinkedIn: https://www.linkedin.com/in/alexander-telford/

Website: https://atelfo.github.io

X: https://twitter.com/atelfo

Substack: https://atelfo.substack.com

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation.

00:00 Introduction and Guest Welcome

00:25 Christian Rommel's Journey in Oncology

03:02 The Importance of Collaboration in Innovation

05:16 Balancing Risk and Reward in Drug Development

18:07 The Role of AI and Data in Modern R&D

22:33 Partnerships and External Learning

26:16 Balancing Legacy and Innovation in Biotech

27:18 Global Expansion and Leadership Diversity

27:27 Courage in Biotech Management

27:54 Inspiration from Roche Genentech

30:26 Commitment to Product Supply and Market Readiness

32:23 Challenges of Global Launches

35:53 Emerging Trends in Pharma: AI and Genetic Medicines

42:20 Decision-Making in Pharma

47:30 Reflections on Academic and Professional Journey

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Christian Rommel;

LinkedIn: https://www.linkedin.com/in/christian-rommel/

Website: https://www.bayer.com/en/innovation/science-research-and-innovation

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies.

00:00 Introduction and Guest Background

00:56 Founding Thebans and Career Highlights

01:43 Leadership at Merck and J&J

02:18 Innovative Approaches at Parabilis Medicines

04:09 Defining and Tackling Undruggable Targets

09:27 Multivalent Drug Design and Bispecifics

13:53 AI and Data Science in Drug Development

19:28 Building and Leading World-Class Teams

25:41 The Importance of Holding Conviction as an Entrepreneur

26:25 Learning from Setbacks in the Biotech Industry

30:10 Challenges and Innovations in Drug Development

32:28 Navigating the Ups and Downs of the Biotech Industry

36:02 The Mission and Future of Parabilis

40:35 Personal Reflections and Advice for Entrepreneurs

46:46 Book Recommendations and Closing Thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Mathai Mammen;

LinkedIn: https://www.linkedin.com/in/mathai-mammen/

Website: https://parabilismed.com/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel’s promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative.

00:00 Introduction and Guest Welcome

00:59 Early Career and Passion for Medicine

02:09 Transition to Industry and GSK Experience

04:50 Building Successful Organizations

07:42 Innovative Models in Pharma

19:03 Joining Candel Therapeutics and Vision for the Future

25:15 Transforming Cancer Treatment

27:24 Challenges in Biotech Market

28:45 Strategic Decisions and Prioritization

31:39 Collaborations and External Partnerships

33:07 Innovative Approaches and Future Prospects

44:23 Leadership and Personal Insights

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Paul Peter Tak;

LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools.

With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.

Chapter Summaries;

00:00 Introduction and Guest Welcome

00:27 Susan Galbraith's Career Journey

02:37 Defining Success in Oncology R&D

05:01 Early Phase Drug Development

07:09 Digital Health and Patient Experience

12:37 Global Collaboration and Innovation

15:05 AI and Future of Oncology

28:08 Diversity and Inclusion in Clinical Trials

33:46 Mentorship and Career Advice

37:45 Challenges and Future Outlook in Oncology

42:06 Closing Remarks and Call to Action

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Susan Gabraith;

• LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk

Follow Mike Rea On;

• Website: https://www.ideapharma.com/
• X: https://x.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/